Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines

Journal of Cancer Research and Clinical Oncology

Volumn 130, Issue 8, 2004, Pages 453-459

  Patel, Manish ^a   Agarwal, Ram ^a   Ardalan, Bach ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

5 FU; CPT 11; FUdR; FUR; Oxaliplatin

Indexed keywords

FLOXURIDINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FLUOROURIDINE; IRINOTECAN; OXALIPLATIN;

ARTICLE; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SURVIVAL;

EID: 4344692589     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0575-6     Document Type: Article

References (40)

1. Agarwal RP, Han T, Fernandez M (2001) Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance. Biochem Pharmacol 61:39-47
2. Ansfield FJ, Curreri AR (1963) Further clinical comparison between 5-Fluorouracil (5-FU) and 5-fluoro-2′-deoxyuridine (5-FUDR). Cancer Chemother Rept 32:101-105
3. Arisawa Y, Sutanto-Ward E, Dalton RD, Sigurdson ER (1994) Short-term intrahepatic FUdR infusion combined with bolus mitomycin C: reduced risk for developing drug resistance. J Surg Oncol 56:75-80
4. Boring CC, Squires TS, Tong T, Montgomery S (1994) Cancer statistics 1994. CA Cancer J Clin 44:7-26
5. Buroker T, Samson M, Correa J, Fraile R, Vaitkevicius VK (1976) Hepatic artery infusion of 5-FUDR after prior systemic 5-fluorouracil. Cancer Treat Rep 60:1277-1279
6. Chou TC, Talay P (1987) Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. New avenues of development cancer chemotherapy. Bristol-Myers Symposium Series. Academic, New York, pp 37-64
7. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418
8. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947
9. Dolnick BJ, Pink JJ (1983) 5-fluorouracil modulation of dihydrofolate reductase RNA levels in methotrexate-resistant KB cells. J Biol Chem 258:13299-13306
10. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041-1047
11. Freshney RI (2000) Culture of animal cells: a manual of basic technique, 4th edn. Wiley-Liss, New York, pp 336-339
12. Geoffroy FJ, Allegra CJ, Sinha B, Grem JL (1994) Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells. Oncol Res 6:581-591
13. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147
14. Glazer RI, Lloyd LS (1982) Association of cell lethality with incorporation of 5-Fluorouracil and 5-Fluorouridine into nuclear RNA in human colon carcinoma cells in culture. Mol Pharmacol 9:468-473
15. Houghton JA, Houghton PJ, Wooten RS (1979) Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine. Cancer Res 39:2406-2413
16. Kessel D, Bruns R, Hall TC (1971) Determinants of responsiveness to 5-Fluorouridine in transplantable murine leukemias. Mol Pharmacol 7:117-121
17. Kufe DW, Major PP (1981) 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem 256:9802-9805
18. Langenbach RJ, Danenberg PV, Heidelberger C (1972) Thymidylate synthetase: mechanism of inhibition by 5-Fluoro-2′-Deoxyridylate. Biochem Biophys Res Commun 48:1565-1571
19. Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel JP, Kunstlinger F, Lecouturier S, Descorps-Declere A (1992) A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 69:893-900
20. Levi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, Letourneau Y, Llory JF, Chollet P, Le Rol A, Focan C (1999) A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. Cancer 85:2532-2540
21. Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Chollet P, Garufi C, Itzhaki M, Dogliotti L (1994) Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 86:1608-1617
22. Levi FA, Zidani R, Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350:681-686
23. Levin RD, Gordon JH (1993) Fluorodeoxyuridine with continuous leucovorin infusion. A phase II clinical trial in patients with metastatic colorectal cancer. Cancer 72:2895-2901
24. Link KH, Aigner KR, Peschau K, Warthona M, Schwemmle K, Danenburg PV (1988) Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT 29 colorectal carcinoma cells. Cancer Chemother Pharmacol 22:58-62
25. Mandel HG, Klubes P, Fernandes DJ (1979) Studies of the antitumor action of 5-Fluorouracil (FU). Bull Cancer 66:49-54
26. Matsuoka H, Yano K, Takiguchi S, Kono A, Seo Y, Saito T, Tomoda H (1995) Advantage of combined treatment of CPT-11 and 5-Fluorouracil. Anticancer Res 15:1447-1452
27. Peters GJ, Van Groeningen CJ, Laurensse EJ, Pinedo HM (1991) Thymidylate synthase from untreated human colorectal cancer and colonie mucosa: enzyme activity and inhibition by 5-fluoro-2′-deoxy-uridine-5′- monophosphate. Eur J Cancer 27:263-267
28. Pinedo HM, Peters GF (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653-1664
29. Richie JP (1992) Intravesical chemotherapy: treatment selection, techniques and results. Urol Clin North Am 19:521-527
30. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-12
31. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914
32. Sanguedolce R, Vultaggio G, Sanguedolce F, Modica G, Li Volsi F, Diana G, Guereio G, Bellanca L, Rausa L (1998) The role of thymidylate synthase levels in the prognosis and the treatment of patients with colorectal cancer. Anticancer Res 18:1515-1520
33. Schmoll HJ, Buchele T, Grothey A, Dempke W (1999) Where do we stand with 5-Fluorouracil? Semin Oncol 26:589-605
34. Shuey DL, Setzer RW, Lau C, Zucker RM, Elstein KH, Narotsky MG, Kavlock RJ, Rogers JM (1995) Biological modeling of 5-fluorouracil developmental toxicity. Toxicology 102:207-213
35. Sobrero AF, Moir RD, Bertino JR, Handschumacher RE (1985) Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-Fluoro-2′-deoxyuridine in the HCT-8 human carcinoma line. Cancer Res 45:3155-3160
36. Song D, Weintjes MG, Gans Y, Au JL (1997) Bladder tissue pharmacokinetics and antitumor effect of intravesicle 5-fluorouridine. Clin Cancer Res 3:901-909
37. Sun D, Urrabaz R, Kelly S, Nguyen M, Weitman S (2002) Enhancement of DNA ligase I level by gemcitabine in human cancer cells. Clin Cancer Res 8:1189-1195
38. van Laar JA, Durrani FA, Rustum YM (1993) Antitumor activity of the weekly push schedule of 5-fluoro-2′-deoxyuridine ± N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26. Cancer Res 53:1560-1564
39. van Laar JA, Rustum YM, Ackland SP, van Groeningen CJ, Peters GJ (1998) Comparison of 5-Fluoro-2′-deoxyuridine with 5-Fluorouracil and their role in the treatment of colorectal cancer. Eur J Cancer 34:296-306
40. Wilkinson DS, Pitot HC (1973) Inhibition of ribosomal ribonucleic acid maturation in Novikoff hepatoma cells by 5-fluorouridine. J Biol Chem 248:63